

24 August 2021

Q1 FY22 Pharma Results review

Sensex:55556

Domestic drives the show; margin pressure may persist in near term

Nifty:16496

Q1 FY22 sales growth for most pharma companies was driven by their India business. Overall sales of the companies we cover grew 11.6% to Rs168.7bn. India growth was much higher in Q1 (44.9%), ahead of the industry's ~37% growth. Challenges in the US and the higher base in API largely offset the benefits of India sales. EBITDA slipped 2.5% to Rs42.1bn. The EBITDA margin shrank 364bps to 25% from higher price erosion in the US, raw material price rises and normalised promotional expense. Adj. PAT declined 2.4% to Rs27.8bn.

Robust performance in India to continue. The India business in the last few quarters bounced back sharply; in Q1 the segment also benefited from the second wave of Covid-19. India sales of companies we cover grew 44.9% to Rs75bn. Companies which had a Covid portfolio and significant focus on acute therapies did well. Alkem (grew 65.3%), Cadila (63.6%), Indoco (45.8%) and Alembic (57.2%) were growth front-runners. Though the pace of India sales is expected to normalise from Q2 FY22, the India business will still be the fastest growing and likely to register a 13-14% CAGR over FY21-23.

Challenges in US generics persist. Covid-19 and a change in prescription patterns (90 days vs 30) benefitted most companies in H1 last year. On a higher base and nominal price erosion, US sales of companies we cover declined 17.2% to \$361m in Q1 FY22. Adherence to regulatory standards and diversification into niche segments of biosimilars, transdermal, injectables and NCE/NDDS would be key catalysts of growth in this region.

EBITDA margins now stabilising. Cost savings from lower promotional and travelling spending expanded EBITDA margins in FY21. In Q1 FY22, the companies we cover contracted 364bps to 25% as most costs returned to pre-Covid'19. Ahead, margin expansion will largely depend on better revenue mixes, internal cost efficiencies and companies' ability to backward integrate.

Road ahead. H1 FY21 was strong as companies benefitted from more supplies of drugs to the US and other regions and a temporary reduction in certain costs. We expect most growth- and margin-related challenges to persist in Q2 FY22. We expect sales of the companies we cover to grow 12.3%/13.3% in FY22/FY23, driven by growth rebounding in the domestic market and launches in the US, while EBITDA and PAT may grow 6.7%/20.3% and 4%/23% in FY22/FY23.

Top picks. We continue to be positive on companies which have a strong domestic business such as **Torrent Pharma** (strong chronic portfolio, productivity improvement and rebound in the US to boost margins), **Ajanta Pharma** (rebound in India sales to improve earnings quality) and CRAMS companies such as **Suven Pharma** (commercialisation of new molecules and forward integration to aid growth).

Abdulkader Puranwala
Research Analyst

Anand Rathi Share and Stock Brokers Limited (hereinafter "ARSSBL") is a full-service brokerage and equities-research firm and the views expressed therein are solely of ARSSBL and not of the companies which have been covered in the Research Report. This report is intended for the sole use of the Recipient. Disclosures and analyst certifications are present in the Appendix.

Fig 1 – Q1 FY22 result snapshot

Rs m	Sales					EBITDA					EBITDA margins					Adj. PAT				
	Companies	1QFY22	1QFY21	4QFY21	YoY (%)	QoQ (%)	1QFY22	1QFY21	4QFY21	YoY (%)	QoQ (%)	1QFY22	1QFY21	bps	4QFY21	bps	1QFY22	1QFY21	4QFY21	YoY (%)
Aarti Drugs	5,800	5,447	5,518	6.5	5.1	797	1,340	1,059	(40.5)	(24.8)	13.7	24.6	(1,085)	19.2	(546)	488	855	766	(42.9)	(36.3)
Ajanta	7,480	6,682	7,568	11.9	(1.2)	2,202	2,232	2,594	(1.3)	(15.1)	29.4	33.4	(397)	34.3	(484)	1,738	1,478	1,593	17.6	9.1
Alembic	13,260	13,413	12,804	(1.1)	3.6	2,359	4,074	3,417	(42.1)	(31.0)	17.8	30.4	(1,258)	26.7	(889)	1,645	3,015	2,507	(45.4)	(34.4)
Alkem	27,314	19,920	21,922	37.1	24.6	5,929	5,217	2,911	13.6	103.7	21.7	26.2	(448)	13.3	843	5,251	4,219	3,172	24.5	65.5
Cadila	39,727	36,272	38,467	9.5	3.3	8,850	8,026	8,536	10.3	3.7	22.3	22.1	15	22.2	9	5,110	4,413	6,625	15.8	(22.9)
Eris	3,493	2,932	2,782	19.1	25.5	1,265	1,041	945	21.6	33.9	36.2	35.5	74	34.0	225	1,067	890	682	19.8	56.3
Granules	8,498	7,356	7,993	15.5	6.3	2,014	1,836	2,020	9.7	(0.3)	23.7	25.0	(126)	25.3	(157)	1,202	1,115	1,276	7.8	(5.8)
Indoco	3,868	2,759	3,051	40.2	26.7	869	487	547	78.6	58.8	22.5	17.6	483	17.9	454	397	170	250	132.7	58.6
IPCA	15,658	15,344	11,147	2.0	40.5	4,131	5,823	2,287	(29.1)	80.6	26.4	38.0	(1,157)	20.5	587	3,039	4,412	1,611	(31.1)	88.6
JB Chem	6,060	5,223	5,285	16.0	14.7	1,637	1,554	1,239	5.3	32.1	27.0	29.8	(275)	23.4	357	1,189	1,194	1,006	(0.5)	18.1
Natco	4,103	5,634	3,313	(27.2)	23.8	1,098	1,711	762	(35.8)	44.1	26.8	30.4	(361)	23.0	376	750	1,228	530	(38.9)	41.5
Neuland	2,009	2,054	2,447	(2.2)	(17.9)	257	338	255	(24.1)	0.7	12.8	16.5	(369)	10.4	236	87	152	173	(42.4)	(49.5)
Pfizer	7,492	5,149	5,348	45.5	40.1	2,857	1,863	1,257	53.4	127.2	38.1	36.2	196	23.5	1,463	1,999	1,245	1,006	60.6	98.8
Suven	2,638	2,382	2,592	10.7	1.8	1,146	1,121	937	2.3	22.3	43.4	47.0	(360)	36.2	729	1,051	915	831	14.8	26.4
Torrent	21,340	20,560	19,370	3.8	10.2	6,770	6,610	5,820	2.4	16.3	31.7	32.1	(43)	30.0	168	3,300	3,210	3,240	2.8	1.9
Total	168,738	151,127	149,605	11.7	12.8	42,181	43,272	34,587	(2.5)	22.0	25.0	28.6	(364)	23.1	188	27,823	28,511	25,268	(2.4)	10.1

Source: Company, Anand Rathi Research

Fig 2 – Q1 FY22 result snapshot

Rs m	Sales					EBITDA					EBITDA margins					Adj. PAT				
	Companies	1QFY22	1QFY21	4QFY21	YoY (%)	QoQ (%)	1QFY22	1QFY21	4QFY21	YoY (%)	QoQ (%)	1QFY22	1QFY21	bps	4QFY21	bps	1QFY22	1QFY21	4QFY21	YoY (%)
Sun Pharma	97,187	75,853	84,314	28.1	15.3	27,412	18,435	20,592	48.7	33.1	28.2	24.3	390	24.2	404	19,954	11,202	14,164	78.1	40.9
Dr Reddy's	49,194	44,293	47,284	11.1	4.0	6,120	11,247	7,002	(45.6)	(12.6)	12.4	25.4	-1,295	14.8	-237	5,708	5,791	5,535	(1.4)	3.1
Cipla	55,044	43,462	46,065	26.6	19.5	13,459	10,487	7,962	28.3	69.0	24.5	24.1	37	17.3	721	8,346	5,779	4,134	44.4	101.9
Lupin	42,702	35,279	37,831	21.0	12.9	9,276	4,881	7,076	90.0	31.1	21.7	13.8	789	18.7	302	5,423	1,069	4,644	407.2	16.8
Aurobindo	57,020	61,584	60,015	(7.4)	(5.0)	12,094	13,424	12,747	(9.9)	(5.1)	21.2	21.8	-60	21.2	-4	7,700	8,380	8,021	(8.1)	(4.0)
Divi's	19,606	17,305	17,882	13.3	9.6	8,521	7,001	7,163	21.7	19.0	43.5	40.5	304	40.1	344	5,571	4,885	4,991	14.0	11.6
Gland Pharma	11,539	8,842	8,877	30.5	30.0	4,363	4,126	3,277	5.7	33.2	37.8	46.7	-887	36.9	89	3,507	3,136	2,604	11.8	34.7
Laurus Labs	12,785	9,743	14,119	31.2	(9.5)	3,954	2,783	4,722	42.1	(16.3)	30.9	28.6	233	33.4	-254	2,416	1,718	2,969	40.6	(18.6)
Abbott India	12,178	10,643	10,955	14.4	11.2	2,652	2,334	2,055	13.6	29.0	21.8	21.9	-13	18.8	304	1,958	1,804	1,525	8.6	28.4
Sanofi India	7,891	7,105	7,251	11.1	8.8	2,471	1,772	1,894	39.4	30.5	31.3	24.9	636	26.1	518	1,783	1,355	1,459	31.6	22.2
GSK Pharma	7,900	6,486	8,138	21.8	(2.9)	1,517	1,141	1,709	33.0	(11.2)	19.2	17.6	161	21.0	-180	1,211	1,108	1,015	9.3	19.3
Total	97,187	75,853	84,314	28.1	15.3	27,412	18,435	20,592	48.7	33.1	28.2	24.3	390	24.2	404	19,954	11,202	14,164	78.1	40.9


Source: Company, Anand Rathi Research

India Formulations

The India business in Q1 FY22 rebounded strongly as demand for medicines surged with the second wave of Covid-19. The companies we cover outpaced the market growth, growing 44.9%, against the market's ~37% growth. Ahead, we expect their India business to grow in mid-teens.

Companies with a focus on acute therapies and Covid-19 drugs outpaced peers. Alkem, Cadila, Alembic and Indoco grew faster.

Fig 3 – India business benefitted from covid sales



Source: Company, Anand Rathi Research


Fig 4 – Q1 India performance of the companies we cover

Domestic formulations (Rs m)	1QFY22	1QFY21	Y/Y %	4QFY21	Q/Q %
Cadila	13,566	8,292	63.6	10,232	32.6
Ajanta	2,290	1,740	31.6	2,180	5.0
Ipca	6,130	4,894	25.2	4,336	41.4
Natco	2,006	1,250	60.5	818	145.2
Indoco	2,151	1,475	45.8	1,392	54.5
Torrent	10,930	9,250	18.2	9,220	18.5
Alembic	4,810	3,060	57.2	3,580	34.4
Pfizer	7,492	5,149	45.5	5,348	40.1
Alkem	19,097	11,550	65.3	14,732	29.6
Eris	3,493	2,932	19.1	2,782	25.5
JB Chemicals	3,130	2,240	39.7	2,210	41.6
Aggregate	75,094	51,833	44.9	56,830	32.1

Source: Company, Anand Rathi Research

Overall, sales of Rs201bn of key pharma companies stemmed from India formulations, which grew 41.8%. Managements of most of the companies are confident of growing this business.

Fig 5 – Aggregate performance of key companies



Source: Company, Anand Rathi Research

Fig 6 – Q1 India performance of key companies

Domestic formulations (Rs m)	1QFY22	1QFY21	Y/Y %	4QFY21	Q/Q %
Cipla	27,100	16,080	68.5	18,070	50.0
Sun Pharma	33,084	23,880	38.5	26,709	23.9
Lupin	16,362	12,854	27.3	12,866	27.2
Dr Reddy's	10,600	6,260	69.3	8,445	25.5
Glenmark	12,250	7,799	57.1	8,238	48.7
GSK Pharma	7,900	6,487	21.8	8,138	-2.9
Sanofi India	6,550	6,035	8.5	6,018	8.8
Abbott India	12,178	10,640	14.5	10,955	11.2

Source: Company, Anand Rathi Research

Management commentary on India sales

Fig 7 – Management commentary on India sales

Companies	Quotes from managements regarding their outlook for their India business
Sun Pharma	India business accounted for about 34% of consolidated sales for Q1. The growth was driven by a combination of core business growth, sale of COVID related products and low base of last year.
Cipla	Significant traction in our One India business led by the strong core portfolio tailwinds in the prescription and Trade Generics business along with the support from the COVID portfolio during the second COVID wave in India. Excluding for COVID, the portfolio momentum continues to be on track with solid double digit growth during the quarter
Cadila Healthcare	The growth was supported by both COVID portfolio as well as good performance of the base business. We gained market share in the anti-diabetic, anti-infective and the nutraceuticals therapeutic areas. "Large part of our future portfolio is driven towards launching low competition or sort of first generic when we launched our biosimilar against the only generic in India and in the world."
Torrent Pharma	Branded generic markets led by India and Brazil, continue to drive growth backed by our top brands and performance of new launches. "I view the double-digit growth for the market should continue even without the COVID drugs going ahead."
Alembic Pharmaceuticals	We saw nice ramp up in our India business despite challenges in related to COVID. "India business we see enough pockets of growth across the portfolio both in Acute, Specialty as well as Veterinary side of it. We continue to perform, we're very confident of the business."
Dr Reddy	Our India business recorded sales of INR1,060 cores with a strong year-on-year growth of 69% and sequential growth of 26%. This strong growth was supported by both COVID portfolio as well as good performance of the base business.
Ajanta Pharma	Growth can be attributed to all three factors during the year which are increase in the market shares, new product launches, and also in a small way increasing the prices of some of the products.
Alkem Labs	65.3% y/y during the quarter, which was majorly driven by strong volume-led growth in our acute therapy. Even adjusting for the low base of last year, the company delivered a robust growth over Q1FY20 base, which was more of a normal quarter for the company.
Glenmark Pharma	So I think Q2 in India obviously will be negative growth for us on the India business. "We will be negative in Q2 because of the high Favipiravir sales we had last year"
JB Chemicals	We have already launched close to 12 to 15 products in last six months in both this new initiatives and couple of products in the world of metabolic. "The domestic market will help us in driving market beating performance, which is a combination of big brands that we have and this market beating performance will also be supported by some of the newer initiatives that we have taken and launching couple of new divisions and around 8 to 10 new brands."
Indoco Remedies	Excellent performance of anti-infective and respiratory therapeutic segments resulted in a robust growth during the quarter.


Source: Company, Anand Rathi Research

US generics

Most of the gains in the US last year are largely fading. US sales of companies we cover declined 17.2% to \$361m.

Greater demand for Covid-19 drugs and change in prescription patterns last year created a higher base for companies. Besides, the base business continues to be eroded every year due to price rises of key products. Zydus Cadila's US sales declined 10.6% to \$194m while Alkem's sales declined 9.3%.

Fig 8 – US performance of companies we cover



Source: Company, Anand Rathi Research

Fig 9 – Q1 US performance of companies we cover


US sales (\$ m)	Q1FY22	Q1FY21	Y/Y %	Q4FY21	Q/Q %
Cadila	194	216	-10.6	205	-5.7
Torrent	36	49	-26.8	37	-1.6
Alkem	81	90	-9.3	73	11.2
Alembic	50	81	-37.9	65	-22.3
Aggregate US sales	361	436	-17.2	380	-4.9

Source: Company, Anand Rathi Research

The US continues to be an important region for listed India companies. Overall, companies had sales of \$1.76bn in Q1 FY22, registering 0.6% growth.

On a weaker base, Sun's US sales grew the fastest (34.8%) in Q1. Aurobindo reported an 11.7% decline in its US sales.

Fig 10 – Aggregate US performance of key companies



Source: Company, Anand Rathi Research

Fig 11 – Q1 US performance of key companies

US sales (\$ m)	Q1FY22	Q1FY21	Y/Y %	Q4FY21	Q/Q %
Sun Pharma	380	282	34.8	370	2.7
Aurobindo	364	412	-11.7	393	-7.4
Dr Reddy's Lab	235	229	2.5	236	-0.6
Lupin	172	157	9.3	195	-11.8
Cipla	141	135	4.4	138	2.2
Glenmark	107	98	8.6	110	-2.7

Source: Company, Anand Rathi Research

Management commentary on US

Fig 12 – Outlook regarding their US business

Companies	Quotes from managements on the outlook for their US business
Sun Pharma	Similar level of price erosion, Sun hasn't seen, because we had larger percentage of product in what you call already highly competitive marketplace. So price erosion, is an impact which is different for different companies. And that's not going to change.
Dr Reddy	We got the downside of the U.S. as some products, we face the price erosion primarily depending on sale, while the big launches are coming up timely wise later.
Aurobindo Pharma	We had slightly tepid growth during the Q1 of current year. We saw some price erosion during the quarter and primarily due to build up of inventory across supply chain, across suppliers due to decreased demand, so price erosion was in, I would say, upper single-digit percentage wise, which is higher than normal.
Cipla	Our portfolio effort, selection and execution have limited the impact of price erosion on our portfolio and we hope to continue this momentum and scale up as new launches come in.
Lupin	US revenues were down sequentially due to competitive pressures on base business products, famotidine in particular, because new competition had entered.
Cadila Healthcare	Reduction in cases of supply disruption in the market resulting in limited one-time opportunities and pricing pressure in some of our products led to this decline." "So, one time buy we have been seeing it in the last couple of years because of disruption in supply chain. In the last six months we have seen this one-time buys have dried up because there is very little issue with supply chain in the US. So, we have not seen any meaningful one time buys in the last six months
Alkem Labs	We had a strong quarter last year, mainly because of some of forward buying done by our customers, a bit of stockpiling and panic buying as well affected that. The other reason has been some loss of market share and obviously price deflation, which has sort of depressed at this particular quarter compared to 12 months ago, but our broad guidance remains similar and we are looking to grow at those numbers.
Glenmark Pharma	On the pricing erosion side, we have seen a bit of an increase then we're probably looking at it in a bit of more around the high single digit level and, of course, this has an impact as we go along


Source: Company, Anand Rathi Research

APIs

The API business of the companies we cover, on a higher base, declined 9.3% to Rs17.2bn. Sequentially, however, sales were 17% higher.

Alembic, Cadila and Granules reported increases of 5.7%, 3.5% and 5.5% respectively.

Fig 13 – APIs continue to be fastest growing segment



Source: Company, Anand Rathi Research


Fig 14 – Q1 performance, API divisions

API sales (Rs m)	Q1FY22	Q1FY21	Y/Y %	Q4FY21	Q/Q %
Aarti Drugs	4,464	4,630	-3.6	3,921	13.8
Alembic	2,790	2,640	5.7	2,140	30.4
Cadila	1,355	1,309	3.5	1,395	-2.9
Granules	2,237	2,121	5.5	1,938	15.4
Indoco	109	222	-51.0	199	-45.4
IPCA	4,144	5,133	-19.3	2,599	59.4
Neuland	1,507	1,500	0.5	1,815	-17.0
Natco	616	1,439	-57.2	708	-13.0
Aggregate US sales	17,222	18,993	-9.3	14,716	17.0

Source: Company, Anand Rathi Research

On an aggregate basis API division sales declined 3.2% to Rs65.9bn.

Fig 15 – Aggregate API sales of key companies



Source: Company, Anand Rathi Research

Fig 16 – Key companies Q1 performance of API divisions

API sales (Rs m)	Q1FY22	Q1FY21	Y/Y %	Q4FY21	Q/Q %
Divi's	9,803	10,207	-4.0	10,729	-8.6
Laurus	5,490	5,220	5.2	7,970	-31.1
Solara	4,056	3,480	16.5	4,442	-8.7
Sun Pharma	5,149	5,537	-7.0	4,357	18.2
Aurobindo	8,119	7,800	4.1	7,943	2.2
Dr Reddy's	7,540	8,553	-11.8	7,915	-4.7
Cipla	3,020	1,840	64.1	2,240	34.8
Lupin	2,459	4,090	-39.9	2,556	-3.8
Glenmark	3,040	2,348	29.5	3,311	-8.2

Source: Company, Anand Rathi Research

Management outlook on APIs

Fig 17 – Outlook regarding APIs

Companies	Quotes from managements on outlook for APIs
Divis Labs	I think there are several things we have taken up in the last one year, investing Rs250bn in backward integration, in top new technology; introducing new technology; up gradation of plants, modern mechanization; and revisiting the processes and improving the yields. I think these are some of the things that caused a positive benefit with green chemistry.
Dr Reddy	API because of the nature of it has relatively high level of fixed cost. When the sales are less, normally you see it also in the margin that fits. So when the sales will go up, also the margins will go up. I don't see any specific issue. We did have some price decrease in some molecules there. So on those molecules, we would see less profitability, but on the other hand, we are going to launch others.
Cipla	Our reported API numbers include a profit share on the commercial supply and API to our partner; our revenue market, the business was slightly impacted by a timing deferral pertaining to in-country currency allocation for our Middle Eastern supplies
Laurus Labs	ARV API recorded a healthy growth. This was led by higher volumes. On sequential basis, sales were moderately-impacted, partly due to demand normalization, which is in line with our expectations. "So our API sale depends on how much of our partners are getting market share and their inventory level, their order book. You can't sell more than what our customer needs.
IPCA Labs	API business we should be able to achieve around 10% kind of growth. Domestic API should be able to do better than that.
Alembic Pharmaceuticals	The API business had phenomenal growth last year. And a lot of the growth last year was due to the COVID-related disruptions. So having said that this quarter, they've done well. I expect them to be close to 10% growth this year
Granules	For the quarter, the gross margins contracted from 59.5% in Q1 FY '21 to 54.2% in Q1 FY '22, mainly due to the reduction in margins on Paracetamol, due to increased KSM pricing
Aarti Drugs	We believe that the worst is behind us in terms of raw material price hike and EBITDA margin are expected to come back to normal level in the coming couple of quarters. We remain confident of obtaining EBITDA margin in the range of around 18% going forward
Solara Active Sciences	The backward integration will go a long way in not just ensuring that we are able to manage our margins in Ibuprofen." "Backward integration will definitely offer is relief in the second half of the year in terms of any potential margin impact.


Source: Company, Anand Rathi Research

Margins

Lower promotional and travelling costs had inflated EBITDA margins of most of the pharma companies last year. On that base, EBITDA margins of companies we cover contracted 364bps y/y to 25%. (23.1% in Q4 FY21). As these costs are now returning to pre-Covid'19 levels, we expect margins to stabilize at these levels.

We factor in a ~25% EBITDA margin for FY22 as promotional spending starts normalising. Beyond that, better revenue mixes, internal cost efficiencies and companies' ability to backward integrate would drive margin expansion.

Fig 18 – EBITDA margins of companies we cover climbed to 25% in Q1 FY22



Source: Company, Anand Rathi Research

Management outlook on margins

Fig 19 – Sustainability of margins

Companies	Quotes from managements on sustainability of margins
Sun Pharma	Expenses in the current quarter have relatively moved up comparatively, however different geographies have different impact of the second wave in India, especially in April, May they were impacted. So overall what we are saying is that, the expenses will inch up as normalization increases, however the company continuously focus heavily on cost optimization and improving efficiencies.
Dr Reddy	FY21 gross margins were high, due to higher export benefit and favorable product mix. The gross margins in current quarter were impacted due to higher price erosion, primarily in U.S. and increase in inventory provisions for a few products.
Aurobindo Pharma	Our endeavor will always be to ensure that we move towards 60% (gross margins). That is what we always have the standard at 58% and move towards 60%. Because of the temporary nature, all these price erosion because of the COVID related and other thing, we had a small setback, but let's see whether it is a one-off or it we'll come to know of it maybe down the line in two quarters
Cipla	So every endeavor is to beat last year's core business profitability, which we believe was in the range of 21% to 22% (EBITDA margins) most quarters other than quarter four where reverse seasonality reduces our margin, but therefore in quarter four also, we'll try to beat last year, we may not be at 21%, 22% but average for the full year, we will come in at that level
Lupin	EBITDA to be 17% to 18% in the second half, which is lower than our earlier guidance of 19% to 20%. We see meaningful bounce back in the second half, driven by increased sales in Albuterol, higher base in India and growth across various markets.
Divis Labs	The margins are getting better and better. It's not one-off, we think they are sustainable. And we always have new projects coming. In the custom synthesis or generic whenever new products come, the margins can be slightly higher." "Right now it is 50-50 (split) between generic and custom synthesis. So that will give you more assurance that the profitability probably can be maintained at these levels.
Ajanta Pharma	I think these margins, which are there currently that definitely can be held.
Alembic Pharmaceuticals	We're temporarily withdrawing this guidance on the Rs50 EPS guidance due to a lot of uncertainty that we're seeing and some softness in the U.S. market."
Glenmark Pharma	Key objectives for FY22, we expect revenue growth of 10% to 15% during the year. We expect to sustain EBITDA margin performance at similar levels of FY21. We would like to guide to a 19% plus margins.
Alkem Labs	EBITDA margin, our guidelines, it was from 19% to 20% for this year, because our endeavor was to improve by 100%. So we remain with our guidance. Looking to better quarter one, we believe 50 to 100 basis points we'll try to improve on that.
IPCA Labs	Guidelines for this year on EBITDA margin side was almost around 25% and in first quarter, we had recorded around 27%. And the trend is likely to be better, so after second quarter, we will revise our guidelines, upward here
JB Chemicals & Pharma	Going forward, we expect that the margin could remain healthy and in the range of last year's margin level despite cost structures reverting to the steady and normal levels.
Laurus Labs	With a better product mix, gross margin, we could able to improve almost by 2%."
Solara Active sciences	EBITDA in the range of 23% to 24%. And obviously, this will be achieved through a combination of building more capacities, focusing on science, increasing our products, working on cost improvement programs"


Source: Company, Anand Rathi Research

Fig 20 – Estimate revision, post-Q1 result

	Revised Estimates						Change %					
	Revenue		EBITDA		Adj. PAT		Revenue		EBITDA		Adj. PAT	
	FY22	FY23	FY22	FY23	FY22	FY23	FY22	FY23	FY22	FY23	FY22	FY23
Aarti Drugs	24.6	29.1	4.4	5.9	2.8	3.9	-4.4	-4.6	-17.4	-10.4	-18.6	-11.1
Ajanta pharma	34.0	39.2	11.4	13.4	8.4	10.1	-0.1	-0.1	-0.1	-0.1	7.2	7.3
Alembic pharmaceutical	54.0	61.9	11.5	14.3	7.6	9.2	-4.0	-5.0	-23.4	-17.8	-24.0	-19.1
Alkem	103.1	110.7	20.7	22.6	16.8	18.2	5.9	3.3	7.6	4.9	8.0	5.1
Cadila	168.2	181.2	36.6	39.2	22.7	24.5	1.0	0.7	1.5	0.5	3.6	2.2
eris	13.9	15.3	4.7	5.3	3.9	4.4	1.4	-0.5	3.2	2.9	0.1	-0.3
granules	36.3	41.3	8.3	9.7	5.1	6.0	-1.1	-1.1	3.9	-0.3	5.0	-0.4
Indoco	15.2	17.5	2.9	3.3	1.3	1.8	0.5	0.4	6.1	0.9	4.7	11.1
IPCA	59.3	66.3	15.1	17.7	10.9	13.0	0.9	0.2	1.6	0.3	2.4	0.8
Jb Chem	24.3	26.7	6.1	7.0	4.9	5.6	6.5	5.8	5.0	5.6	5.1	5.6
Natco	23.3	42.5	8.2	20.2	6.0	15.4	-3.7	-2.0	-4.0	-1.8	-4.2	-1.9
Neuland	10.3	11.7	1.5	1.8	0.7	0.9	-1.1	-3.1	-8.0	-10.7	-20.5	-23.1
Pfizer	26.2	28.9	8.8	9.7	6.7	7.4	4.8	4.0	19.3	15.4	10.5	6.9
Suven	12.0	14.2	5.4	6.5	4.4	5.3	1.1	3.7	1.1	3.7	1.6	4.9
Torrent	89.3	100.1	27.9	32.2	13.4	16.6	-0.1	0.0	1.8	2.9	-5.2	-6.3

Source: Company, Anand Rathi Research

Fig 21 – Price performance




Source: Bse

Fig 22 – Valuation Summary

Company	RATING	CMP	TP	M Cap	EPS (Rs)			PE (x)			EV/EBITDA (x)			RoE (%)		
		(Rs)	(Rs)	(Rs bn)	FY21	FY22e	FY23e	FY21	FY22e	FY23e	FY21	FY22e	FY23e	FY21	FY22e	FY23e
Aarli Drugs	Buy	587	836	62.8	30.1	25.4	41.8	19.5	23.1	14.0	15.6	17.1	10.8	35.8	23.6	30.9
Ajanta	Buy	2237	2795	210.0	75.2	96.6	116.4	29.7	23.1	19.2	15.4	17.5	14.4	23.4	25.0	24.3
Alembic	Hold	734	955	179.0	59.9	38.6	46.7	12.2	19.0	15.7	7.0	16.2	12.2	28.2	14.0	15.2
Alkem	Hold	3792	3644	415.0	132.6	140.1	151.8	28.6	27.1	25.0	16.8	19.5	17.4	23.4	21.0	19.8
Zydus Cadila	Sell	547	522	577.2	21.7	22.1	23.9	25.2	24.7	22.9	18.3	16.5	14.9	19.0	16.4	15.8
Eris	Hold	731	804	104.8	26.2	28.6	32.1	27.9	25.5	22.7	18.3	20.8	17.9	24.7	22.4	21.2
Granules India	Hold	326	392	92.0	22.2	20.4	24.2	14.7	16.0	13.5	11.3	11.5	9.6	27.4	21.1	20.9
Indoco Remedies	Sell	443	348	40.7	10.1	13.6	19.1	43.9	32.5	23.2	19.3	14.7	12.3	12.8	15.1	18.0
Ipca Labs	Hold	2562	2462	274.4	88.4	86.4	102.6	29.0	29.6	25.0	17.8	17.3	14.3	26.8	21.1	20.8
JB Chemicals	Hold	1696	1890	137.2	58.0	63.8	72.7	29.3	26.6	23.3	16.1	20.7	17.6	27.6	24.9	23.9
Natco Pharma	Hold	900	1139	188.9	24.2	33.2	84.4	37.2	27.1	10.7	30.6	22.3	9.0	11.2	13.9	29.8
Neuland	Sell	1533	1268	24.2	62.5	55.2	70.5	24.5	27.8	21.8	17.3	17.1	13.9	10.8	8.7	10.2
Pfizer	Buy	5732	6520	270.8	108.8	138.0	152.7	52.7	41.5	37.5	27.5	28.9	25.7	17.2	24.1	22.5
Suven Pharma	Buy	549	630	138.2	14.2	17.5	21.0	38.6	31.4	26.2	31.3	25.5	20.7	35.8	32.9	31.0
Torrent Pharma	Buy	3062	3664	508.4	74.0	79.4	98.2	41.4	38.5	31.2	22.1	19.4	16.5	23.5	21.6	23.5

Source: Anand Rathi Research

Fig 26 – PE bands



Source: Bloomberg, Anand Rathi Research

Appendix

Analyst Certification

The views expressed in this Research Report accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report. The research analysts are bound by stringent internal regulations and also legal and statutory requirements of the Securities and Exchange Board of India (hereinafter "SEBI") and the analysts' compensation are completely delinked from all the other companies and/or entities of Anand Rathi, and have no bearing whatsoever on any recommendation that they have given in the Research Report.

Anand Rathi Ratings Definitions

Analysts' ratings and the corresponding expected returns take into account our definitions of Large Caps (>US\$1bn) and Mid/Small Caps (<US\$1bn) as described in the Ratings Table below:

Ratings Guide (12 months)	Buy	Hold	Sell
Large Caps (>US\$1bn)	>15%	5-15%	<5%
Mid/Small Caps (<US\$1bn)	>25%	5-25%	<5%

Research Disclaimer and Disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014

Anand Rathi Share and Stock Brokers Ltd. (hereinafter refer as ARSSBL) (Research Entity) is a subsidiary of Anand Rathi Financial Services Ltd. ARSSBL is a corporate trading and clearing member of Bombay Stock Exchange Ltd, National Stock Exchange of India Ltd. (NSEIL), Multi Stock Exchange of India Ltd (MCX-SX) and also depository participant with National Securities Depository Ltd (NSDL) and Central Depository Services Ltd. ARSSBL is engaged in the business of Stock Broking, Depository Participant and Mutual Fund distributor.

The research analysts, strategists, or research associates principally responsible for the preparation of Anand Rathi research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors and firm revenues.

General Disclaimer: This Research Report (hereinafter called "Report") is meant solely for use by the recipient and is not for circulation. This Report does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through ARSSBL nor any solicitation or offering of any investment /trading opportunity on behalf of the issuer(s) of the respective security (ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by ARSSBL to be reliable. ARSSBL or its directors, employees, affiliates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, affiliates or representatives of ARSSBL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. The price and value of the investments referred to in this Report and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. ARSSBL does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding taxation aspects of any potential investment.

Opinions expressed are our current opinions as of the date appearing on this Research only. We do not undertake to advise you as to any change of our views expressed in this Report. Research Report may differ between ARSSBL's RAs and/ or ARSSBL's associate companies on account of differences in research methodology, personal judgment and difference in time horizons for which recommendations are made. User should keep this risk in mind and not hold ARSSBL, its employees and associates responsible for any losses, damages of any type whatsoever.

ARSSBL and its associates or employees may; (a) from time to time, have long or short positions in, and buy or sell the investments in/ security of company (ies) mentioned herein or (b) be engaged in any other transaction involving such investments/ securities of company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) these and other activities of ARSSBL and its associates or employees may not be construed as potential conflict of interest with respect to any recommendation and related information and opinions. Without limiting any of the foregoing, in no event shall ARSSBL and its associates or employees or any third party involved in, or related to computing or compiling the information have any liability for any damages of any kind.

Details of Associates of ARSSBL and Brief History of Disciplinary action by regulatory authorities & its associates are available on our website i.e. www.rathionline.com

Disclaimers in respect of jurisdiction: This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject ARSSBL to any registration or licensing requirement within such jurisdiction(s). No action has been or will be taken by ARSSBL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. ARSSBL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to ARSSBL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India.

Statements on ownership and material conflicts of interest, compensation - ARSSBL and Associates

Answers to the Best of the knowledge and belief of ARSSBL/ its Associates/ Research Analyst who is preparing this report

Research analyst or research entity or his associate or his relative has any financial interest in the subject company and the nature of such financial interest.	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have actual/beneficial ownership of one per cent or more securities of the subject company	No
ARSSBL/its Associates/ Research Analyst/ his Relative have any other material conflict of interest at the time of publication of the research report?	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have managed or co-managed public offering of securities for the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months	No
ARSSBL/its Associates/ Research Analyst/ his Relative have received any compensation or other benefits from the subject company or third party in connection with the research report	No
ARSSBL/its Associates/ Research Analyst/ his Relative have served as an officer, director or employee of the subject company.	No

Other Disclosures pertaining to distribution of research in the United States of America

This research report is a product of ARSSBL, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by ARSSBL only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, ARSSBL has entered into an agreement with a U.S. registered broker-dealer, Cabrera Capital Markets. ("Cabrera"). Transactions in securities discussed in this research report should be effected through Cabrera or another U.S. registered broker dealer.

1. ARSSBL or its Affiliates may or may not have been beneficial owners of the securities mentioned in this report.
2. ARSSBL or its affiliates may have or not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
3. ARSSBL or its affiliates may have or not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
4. However, one or more of ARSSBL or its Affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon, either on their own account or on behalf of their clients.
5. As of the publication of this report, ARSSBL does not make a market in the subject securities.
6. ARSSBL or its Affiliates may or may not, to the extent permitted by law, act upon or use the above material or the conclusions stated above, or the research or analysis on which they are based before the material is published to recipients and from time to time, provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.

© 2021. This report is strictly confidential and is being furnished to you solely for your information. All material presented in this report, unless specifically indicated otherwise, is under copyright to ARSSBL. None of the material, its content, or any copy of such material or content, may be altered in any way, transmitted, copied or reproduced (in whole or in part) or redistributed in any form to any other party, without the prior express written permission of ARSSBL. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of ARSSBL or its affiliates, unless specifically mentioned otherwise.

Additional information on recommended securities/instruments is available on request.

ARSSBL registered address: Express Zone, A Wing, 9th Floor, Western Express Highway, Diagonally Opposite Oberoi Mall, Malad (E), Mumbai – 400097.
Tel No: +91 22 6281 7000 | Fax No: +91 22 4001 3770 | CIN: U67120MH1991PLC064106.